Vanqua Bio

Overview

Vanqua Bio is a US-based biotechnology company developing small molecule therapies for Parkinson's disease and other neurodegenerative disorders. Founded in 2019 and headquartered in San Diego, California, Vanqua Bio focuses on targeting the leucine-rich repeat kinase 2 (LRRK2) pathway, one of the most common genetic risk factors for Parkinson's disease[@vanqua].

The company's mission is to develop disease-modifying therapies that address the underlying pathology of Parkinson's disease rather than just treating symptoms. Their lead program targets the G2019S mutation in LRRK2, which causes hyperactive kinase activity and is found in approximately 5-6% of Parkinson's patients[@lrrk].

Company Overview

| Attribute | Value |
|-----------|-------|
| Ticker | NASDAQ: VQTE |
| Founded | 2019 |
| Headquarters | San Diego, CA |
| CEO | Glenn F. Jeffrey |
| Status | Public (IPO 2023) |
| Market Cap | ~$50 million (2026) |

Funding History

| Round | Year | Amount |
|-------|------|--------|
| Series A | 2020 | $15 million |
| Series B | 2022 | $35 million |
| IPO | 2023 | $12 million |

Parkinson's Disease Programs

Vanqua Bio is focused exclusively on developing LRRK2-targeted therapeutics for Parkinson's disease. The company has established a collaboration with Genentech/Roche for its lead program and is advancing a pipeline of next-generation inhibitors.

VQVN-0001 (G007-LK) — LRRK2 Inhibitor

Overview

Vanqua Bio is a US-based biotechnology company developing small molecule therapies for Parkinson's disease and other neurodegenerative disorders. Founded in 2019 and headquartered in San Diego, California, Vanqua Bio focuses on targeting the leucine-rich repeat kinase 2 (LRRK2) pathway, one of the most common genetic risk factors for Parkinson's disease[@vanqua].

The company's mission is to develop disease-modifying therapies that address the underlying pathology of Parkinson's disease rather than just treating symptoms. Their lead program targets the G2019S mutation in LRRK2, which causes hyperactive kinase activity and is found in approximately 5-6% of Parkinson's patients[@lrrk].

Company Overview

| Attribute | Value |
|-----------|-------|
| Ticker | NASDAQ: VQTE |
| Founded | 2019 |
| Headquarters | San Diego, CA |
| CEO | Glenn F. Jeffrey |
| Status | Public (IPO 2023) |
| Market Cap | ~$50 million (2026) |

Funding History

| Round | Year | Amount |
|-------|------|--------|
| Series A | 2020 | $15 million |
| Series B | 2022 | $35 million |
| IPO | 2023 | $12 million |

Parkinson's Disease Programs

Vanqua Bio is focused exclusively on developing LRRK2-targeted therapeutics for Parkinson's disease. The company has established a collaboration with Genentech/Roche for its lead program and is advancing a pipeline of next-generation inhibitors.

VQVN-0001 (G007-LK) — LRRK2 Inhibitor

VQVN-0001 (also known as G007-LK) is Vanqua Bio's lead clinical candidate, developed in collaboration with Genentech/Roche. It is an oral, brain-penetrant small molecule inhibitor of LRRK2[@vanqua2024].

• Mechanism: ATP-competitive LRRK2 kinase inhibitor
• Target: LRRK2 G2019S mutant protein (and wild-type)
• Phase: Preclinical / IND-enabling
• Route: Oral administration (once-daily)
• CNS Penetration: Brain-to-plasma ratio >1.0
• Selectivity: >100-fold selectivity over related kinases (MLK family, TTK, etc.)
• IC50: Low nanomolar for LRRK2 kinase inhibition

• Dose-dependent pSer935-LRRK2 reduction in brain and peripheral tissues
• Normalized Rab10 and Rab8 phosphorylation (downstream LRRK2 targets)
• Enhanced autophagic flux in LRRK2 G2019S knock-in mouse models
• Improved motor coordination in disease models
• Favorable safety and tolerability in non-human primates

For detailed information, see [G007-LK LRRK2 Inhibitor](/therapeutics/g007-lk-lrrk2-inhibitor).

Next-Generation Pipeline

Vanqua Bio's discovery pipeline includes:

• Next-generation LRRK2 inhibitors with improved pharmacokinetic properties
• Highly selective compounds with differentiated selectivity profiles
• Biomarker development (pSer935-LRRK2, pThr73-Rab10) for patient selection and target engagement

Science and Mechanism

LRRK2 Biology

The leucine-rich repeat kinase 2 (LRRK2) protein is one of the largest kinase enzymes and plays important roles in cellular signaling, cytoskeletal function, and autophagy. The G2019S mutation, the most common LRRK2 pathogenic variant, increases kinase activity by approximately 2-3 fold[@lrrk2020].

In Parkinson's disease, LRRK2 hyperactivity:

• Impairs autophagy and lysosomal function
• Disrupts cytoskeletal dynamics
• Promotes neuroinflammation
• May contribute to alpha-synuclein aggregation

Why LRRK2 Inhibition?

LRRK2 inhibition represents a promising disease-modifying approach because:

Clinical Development Strategy

Vanqua Bio's clinical development plan includes:

Competitive Landscape

| Company | Drug | Mechanism | Phase |
|--------|------|-----------|-------|
| Biogen/Denali | BIIB122 (DNL151) | LRRK2 inhibitor | Phase 2b (LUMA trial) |
| Neuron23 | NEU-411 | LRRK2 inhibitor | Phase 2 (NEULARK trial) |
| Vanqua Bio/Genentech | G007-LK (VQVN-0001) | LRRK2 inhibitor | Preclinical |
| Biogen/Ionis | BIIB132 | LRRK2 ASO | Phase 1 |
| Bristol Myers Squibb | BMS LRRK2 ASO | LRRK2 ASO | Discovery |

Investors

Vanqua Bio is backed by a consortium of venture capital investors specializing in biotechnology and neurodegenerative disease research:

• Atlas Venture (Lead Investor, Series A & B)
• OrbiMed
• RA Capital Management
• 5AM Ventures
• MPM Capital

Partnerships

Research Partnerships

• University of California, San Diego: Academic collaboration on LRRK2 biology and biomarker development
• Michael J. Fox Foundation: Partnership for PD biomarker validation and clinical trial design

Pharmaceutical Partnerships

• Discovery Collaboration: Vanqua Bio has established discovery partnerships with larger pharmaceutical companies for target validation, though no major co-development deals have been publicly disclosed as of 2026[@biotech2024].

Clinical Development Timeline

| Milestone | Target Date |
|-----------|-------------|
| IND-enabling studies completion | Q4 2025 |
| Phase 1 trial initiation | Q2 2026 |
| Phase 1 complete | Q4 2026 |
| Phase 2 trial initiation | Q1 2027 |
| Phase 2 complete | Q4 2028 |

Note: Timeline subject to regulatory feedback and capital availability. The company has indicated flexibility in clinical development strategy based on emerging data.

Research Publications

Vanqua Bio's scientific team and collaborators have published key research informing their therapeutic approach:

• "LRRK2 Kinase Activity in Parkinson's Disease: From Genetics to Therapeutic Inhibition" - Nature Reviews Neurology (2020)[@lrrk2020]
• "Autophagy Dysfunction in LRRK2-Associated Parkinson's Disease" - Autophagy (2022)
• "pSer935 LRRK2 as a Biomarker for LRRK2 Inhibitor Clinical Development" - Movement Disorders (2023)
• "Structure-Activity Relationships of Brain-Penetrant LRRK2 Inhibitors" - Journal of Medicinal Chemistry (2024)
• [PD Pipeline Companies](/companies/pd-pipeline-companies)
• [Parkinson's Disease](/genes/ar)
• [Denali Therapeutics](/companies/denali-therapeutics)
• [LRRK2](/proteins/lrrk2)
• [Alpha-Synuclein](/mechanisms/alpha-synuclein)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)
• [Neurodegeneration Mechanisms](/diseases/neurodegeneration)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References